Adial Pharmaceuticals (NASDAQ: ADIL) details evolving AD04 development and IP
Rhea-AI Filing Summary
Adial Pharmaceuticals reported its first quarter 2026 results and provided a business update focused on its lead candidate AD04 for Alcohol Use Disorder. The company highlighted evolving U.S. regulatory views suggesting, in some cases, a single adequate and well-controlled trial plus confirmatory evidence may support approval, potentially reducing the need for two full Phase 3 studies.
Adial noted growing support for patient-centered endpoints in Alcohol Use Disorder, such as reductions in heavy drinking and cravings, which align with AD04’s clinical profile and prior ONWARD Phase 3 data showing reduced drinking without major safety concerns. The company also outlined a collaboration framework with Molteni Farmaceutici for a potential European commercialization pathway for AD04, subject to a definitive agreement.
Adial is reinforcing its intellectual property, including an international patent application that, if granted, is expected to protect AD04 through at least 2045. The company plans a new Phase 3 program and broader addiction indications but emphasized that progress depends on obtaining sufficient funding or a strategic partner, and it is actively pursuing financing and strategic alternatives.
Positive
- None.
Negative
- None.
Insights
Adial ties AD04 strategy to shifting AUD regulatory and policy trends.
Adial Pharmaceuticals links its AD04 development plan to evolving FDA flexibility and broader policy shifts in Alcohol Use Disorder. The discussion of single pivotal trials plus confirmatory evidence, where scientifically justified, could lower late-stage trial cost and complexity for qualifying programs.
The company also points to growing acceptance of patient-centered endpoints such as reduced heavy drinking and cravings, and to bipartisan initiatives for veterans with AUD. These trends appear consistent with AD04’s ONWARD Phase 3 data in heavy drinkers and its precision-medicine positioning, but actual impact depends on future regulatory interactions and trial designs.
Strategically, Adial is pursuing a Molteni Farmaceutici collaboration framework for Europe and strengthening patents expected to protect AD04 through at least 2045. However, the company states that advancing a new Phase 3 program and broader indications will require additional funding or a strategic partner, so subsequent disclosures on financing outcomes will be important for understanding execution risk.
8-K Event Classification
Key Figures
Key Terms
Phase 3 clinical trial financial
Alcohol Use Disorder (AUD) medical
New Drug Application (NDA) regulatory
precision medicine medical
forward-looking statements regulatory
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
| (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices and zip code)
(
(Registrant’s telephone number including area code)
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
|
The ((Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 11, 2026, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for its quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are furnished with this Current Report on Form 8-K:
| Exhibit Number |
Exhibit Description | |
| 99.1 | Press Release, issued by Adial Pharmaceuticals, Inc. on May 11, 2026 | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 11, 2026 | ADIAL PHARMACEUTICALS, INC. | |
| By: | /s/ Cary J. Claiborne | |
| Name: | Cary J. Claiborne | |
| Title: | President and Chief Executive Officer | |
2
Exhibit 99.1
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Glen Allen, VA – May 11, 2026 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026.
“We are very encouraged by the continued progress we have made in early 2026 to advance AD04 toward late-stage development, particularly in light of several important regulatory and strategic developments that we believe meaningfully strengthen our path forward,” said Cary Claiborne, Chief Executive Officer of Adial. “Most notably, recent Food and Drug Administration (FDA) policy discussions indicating that, in certain scientifically justified cases, approval may be supported by one adequate and well-controlled study together with confirmatory evidence, rather than the traditional requirement of two independent pivotal trials, represents an increased emphasis on the FDA’s existing flexibility in the development landscape. Given that Phase 3 trials are the most capital-intensive stage of development, this evolving framework could substantially reduce costs, improve capital efficiency, and accelerate our potential timeline to NDA submission.”
“At the same time, we are seeing growing bipartisan support and regulatory momentum toward more patient-centered clinical trial endpoints in Alcohol Use Disorder (AUD), including measures such as reductions in heavy drinking, cravings, and overall disease severity, where such measures reflect clinically meaningful improvement for patients, rather than strict abstinence alone. This shift is further reinforced by recent Congressional action, including the introduction of bipartisan legislation aimed at expanding access to emerging therapies for veterans suffering from AUD, which supports investigational treatments aligned with the government’s updated definition of recovery, including non-abstinence-based approaches and harm reduction outcomes. These developments are highly aligned with the clinical profile and intended real-world benefit of AD04, and we believe they further validate our approach to developing a differentiated, precision medicine treatment for AUD.”
“From a strategic standpoint, we were also pleased to establish a collaboration framework with Molteni Farmaceutici, which represents an important first step toward building a commercial pathway for AD04 in Europe, subject to the execution of a definitive agreement. Molteni’s deep expertise in addiction therapeutics and established infrastructure across European markets make them a strong potential partner as we look to expand AD04’s global reach. In parallel, we continue to strengthen our intellectual property position, including the publication of our international patent application, which, if granted, is expected to extend protection for AD04 through at least 2045, further reinforcing the long-term value of our platform.”
“Taken together, these regulatory developments, policy tailwinds, strategic partnerships, and IP advancements position us to advance AD04 with increasing clarity, efficiency, and confidence if we are able to obtain sufficient funding or a strategic partner. We are actively pursuing financing through various potential sources and other strategic plans and strategic alternatives. We believe we have built a strong foundation not only for a successful Phase 3 program, but ultimately for delivering a meaningful, genetically targeted treatment option to patients suffering from Alcohol Use Disorder.”
First Quarter 2026 Financial Results
| ● | Cash and cash equivalents were $4.6 million as of March 31, 2026, compared to $5.9 million as of December 31, 2025. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the second half of 2026 based on currently committed development plans. |
| ● | Research and development expenses decreased by approximately $314 thousand (42%) to $433 thousand during the three months ended March 31, 2026, compared to $747 thousand for the three months ended March 31, 2025. The decrease was mainly due to decreased CMC and no new data analytics activity in the three months ended March 31, 2026 as compared to the same period in 2025. |
| ● | General and administrative expenses increased by approximately $49 thousand (3%) to $1.6 million during the three months ended March 31, 2026 compared to $1.5 million for the three months ended March 31, 2025. The increase was mainly due to an increase in business development costs incurred in the three months ended March 31, 2026 as compared to the same period in 2025. |
| ● | Net Loss was $2.0 million for the three months ended March 31, 2026, compared to a net loss of $2.2 million for the three months ended March 31, 2025. The decrease in net loss was primarily driven by lower R&D spending and a milestone gain of approximately $150 thousand that was recognized in the three months ended March 31, 2025 which did not occur during the three months ended March 31, 2026. |
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational product candidate, AD04, is being developed as a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Adial is currently planning to conduct a new Phase 3 clinical trial program for the treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary diagnostic genetic test, pending availability of adequate funds. The Company’s recent ONWARD Phase 3 clinical trial showed promising results in reducing drinking in heavy drinking patients, with no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
2
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding advancing AD04 toward late-stage development; regulatory and strategic developments strengthening the Company’s path forward; the evolving framework of the FDA substantially reducing costs, improving capital efficiency and accelerating the Company’s potential timeline to NDA submission; regulatory developments related to AUD validating the Company’s approach to developing a differentiated, precision medicine treatment for AUD; the Company building a commercial pathway for AD04 in Europe, including by entering into a final definitive agreement to establish a partnership with Molteni covering the commercialization of AD04 in Europe; expanding AD04’s global reach; patent protection for AD04 being extended through at least 2045, further reinforcing the long-term value of its platform; regulatory developments, policy tailwinds, strategic partnerships, and IP advancements positioning the Company to advance AD04 with increasing clarity, efficiency, and confidence if it is able to obtain sufficient funding or a strategic partner; actively pursuing financing through various potential sources and other strategic plans and strategic alternatives; the Company having buillt a strong foundation not only for a successful Phase 3 program, but ultimately for delivering a meaningful, genetically targeted treatment option to patients suffering from AUD; and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect the Company’s current views, and they involve certain risks and uncertainties, including, among others, the Company’s ability to pursue its regulatory strategy; the Company’s ability to commence its planned Phase 3 clinical trial; the Company’s ability to advance ongoing partnering discussions, including finalizing and entering into a definitive agreement regarding the planned partnership with Molteni; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to develop strategic partnership opportunities and maintain collaborations; the Company’s ability to obtain or maintain the capital or grants necessary to fund its research and development activities; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for specific indications; acceptance of the Company’s product candidates in the marketplace and the successful development, marketing or sale of its products; the Company’s ability to maintain its license agreements; the continued maintenance and growth of the Company’s patent estate and its ability to retain its key employees or maintain the Company’s Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. Adial undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com
3